-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 8-9, 2022, the 15th Suzhou Hematology Summit, an important academic event in the field of hematology, was held
in Suzhou.
Since its inception in 2008, the Suzhou Hematology Summit has shared many cutting-edge academic advances
for many hematology colleagues and well-known scholars in the field of hematology.
This conference invited well-known hematology experts at home and abroad to conduct in-depth discussions
on the research and development of new drugs in hematology, the construction of big data platform, the work plan of the working group on rare blood diseases, and the blood innovation forum.
On this occasion, Yimaitong specially invited Professor Huang Haiwen from the First Affiliated Hospital of Soochow University to interpret the application status and future prospects of autologous hematopoietic stem cell transplantation in lymphoma based on clinical experience, so as to feed readers!
The advent of the new drug era has provided more opportunities for the "cure" of hematological diseases, but hematopoietic stem cell transplantation still occupies an important position
in the overall treatment of hematological diseases.
Can you briefly talk about the progress of autologous hematopoietic stem cell transplantation in lymphoma treatment and the timing of different lymphoma autologous transplantation?
With the development of the times, there are more and more treatment methods for lymphoma, including targeted therapy, immunotherapy represented by CAR-T, autologous hematopoietic stem cell transplantation, allogeneic hematopoietic stem cell transplantation, etc.
, but autologous hematopoietic stem cell transplantation is still the most important treatment for
patients with relapsed/refractory lymphoma.
Autologous hematopoietic stem cell transplantation is also recommended for first-line treatment
of newly-high-risk lymphomas, such as high-risk diffuse large B-cell lymphoma, high-risk peripheral T-cell lymphoma, and young, aggressive mantle cell lymphoma.
In the future, targeted therapy, immunotherapy and autologous hematopoietic stem cell transplantation can be combined to give full play to their respective advantages in order to better help lymphoma patients prolong survival and improve their quality of life
.
Yimaitong: In recent years, the development of innovative drugs has brought infinite possibilities for the treatment of lymphoma, such as the approval of CD19 CAR-T, and the question of whether autologous hematopoietic stem cell transplantation can be replaced in the era of new drugs in the clinic.
Whether the approval of CAR-T cell therapy products means that autologous hematopoietic stem cell transplantation is about to be replaced, which is a matter
of great concern to clinicians and patients.
The number of autologous hematopoietic stem cell transplants has decreased significantly after the launch of CAR-T products in the United States, which cannot be ignored because the United States has included CAR-T cell therapy in medical insurance, reducing the economic burden of
patients.
In China, if patients can participate in clinical trials, CAR-T cell therapy also shows great advantages, but the expensive price of CAR-T cell therapy is a challenge
after its commercialization.
Autologous hematopoietic stem cell transplantation is a more effective and economical treatment, and is the first choice for chemotherapy-sensitive patients
.
The combination of autologous hematopoietic stem cell transplantation and new treatment methods such as CAR-T cell therapy to further improve the remission rate and prolong the survival of patients may be the development direction
of lymphoma treatment in the future.
Yimaitong: The First Affiliated Hospital of Soochow University has accumulated rich experience in the diagnosis and treatment of lymphoma, can you briefly talk about the characteristics of lymphoma diagnosis and treatment in the First Affiliated Hospital of Soochow University?
The First Affiliated Hospital of Soochow University is also the National Clinical Research Center for
Hematology Diseases.
At present, our center can skillfully apply
lymphoma treatment methods such as traditional immunochemotherapy to targeted therapy, cellular immunotherapy, autologous hematopoietic stem cell transplantation, and allogeneic hematopoietic stem cell transplantation that can be used in European and American countries.
Moreover, there are many clinical trials in our center, which can provide more treatment opportunities and new treatment methods
for patients with relapsed/refractory diseases.
Therefore, the characteristics and advantages of lymphoma diagnosis and treatment in the First Affiliated Hospital of Soochow University are that there are more treatments and means for treating relapsed/refractory patients, and relapsed/refractory patients can receive more and better treatment
in our center.
Professor Haiwen Huang
The First Affiliated Hospital of Soochow University
Doctor of Medicine, Chief Physician, Professor, Doctoral Supervisor, Head of Lymphoma Ward
Member of the Lymphocytic Disease Group of the Hematology Branch of the Chinese Medical Association
Member of the Lymphatic Hematology Group of the Oncology Branch of the Chinese Medical Association
Vice Chairman of the Lymphoma Professional Committee of the Chinese Medical Education Association
Member of the Lymphoma Group of the Hematology and Oncology Committee of the Chinese Anti-Cancer Association
Member of the Working Group on Chronic Lymphocytic Leukemia of the Chinese Anti-Cancer Association
Vice Chairman of Jiangsu Lymphoma Professional Committee
Vice Chairman of Jiangsu Lymphoma Alliance
